{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-110653","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.464938+00:00","generated_at":"2026-06-09T16:38:35.353904+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edesa Biotech secures $10M revolving credit facility from CEO; $3.5M available, matures March 2026","bullets":["Revolving credit facility of up to $10M from Pardeep Nijhawan Medicine Professional Corp., controlled by CEO.","Initial credit limit of $3.5M; facility matures March 31, 2026 unless terminated by 90 days' notice.","Interest at CIBC US Base Rate plus 3% per annum; monthly standby fee of 1.5% on unused portion.","Repayment due within 5 business days of receiving funds from Canada's Strategic Innovation Fund (SIF).","Borrowing base tied to eligible SIF grant and license fee receivables; 85% advance rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-110653","json":"https://secwatch.observer/filing/0001104659-23-110653.json","markdown":"https://secwatch.observer/filing/0001104659-23-110653.md","text":"https://secwatch.observer/filing/0001104659-23-110653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000110465923110653/0001104659-23-110653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000110465923110653/tm2328896d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T16:38:35.353904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a336075559baa89c8af69a54f21b55b22fac3a2","claim":"Edesa Biotech, Inc. entered into Credit Agreement with Pardeep Nijhawan Medicine Professional Corporation valued at $10 million (effective 2023-10-20).","evidence_excerpt":"Effective October 20, 2023, the Company entered into a Credit Agreement (the “ Credit Agreement ”) with Pardeep Nijhawan Medicine Professional Corporation (the “ Lender ”), an entity controlled by Dr. Nijhawan, providing for an unsecured revolving credit facility (the “ Facility ”) in the principal amount of up to $10 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000110465923110653/0001104659-23-110653-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Pardeep Nijhawan Medicine Professional Corporation"},{"label":"Value","value":"$10 million"},{"label":"Effective","value":"2023-10-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}